SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

被引:119
|
作者
Lam, Carolyn S. P. [1 ,2 ,3 ,4 ]
Chandramouli, Chanchal [1 ]
Ahooja, Vineeta [5 ]
Verma, Subodh [6 ,7 ]
机构
[1] Natl Heart Ctr Singapore, 5 Hosp Dr, Singapore 169609, Singapore
[2] Duke Natl Univ Singapore, Med Sch, Singapore, Singapore
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] George Inst Global Hlth, Newtown, Tas, Australia
[5] Heart Hlth Inst, Toronto, ON, Canada
[6] Univ Toronto, Keenan Res Ctr Biomed Sci, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
[7] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada
来源
关键词
heart failure; SGLT-2; inhibitors; type 2 diabetes mellitus; unmet needs; ASSOCIATION TASK-FORCE; 2013 ACCF/AHA GUIDELINE; NONCARDIAC COMORBIDITIES; CARDIOVASCULAR OUTCOMES; AMERICAN-COLLEGE; DIABETES-MELLITUS; EJECTION FRACTION; NA+/H+-EXCHANGER; CARDIAC FIBROSIS; FOCUSED UPDATE;
D O I
10.1161/JAHA.119.013389
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页数:12
相关论文
共 50 条
  • [31] SGLT-2 inhibitors in the treatment of heart failure with reduced ejection fraction: a systematic review
    Paffer, Pedro Toscano
    Bezerra de Albuquerque Cortez, Isabelly Regina
    Damasso Lisboa Costa, Marcelo Danilo
    da Costa Neta, Maria Rosalia
    Tavares Pedroza Monteiro, Marina Lins
    Paffer, Matheus Toscano
    Terra Lopes, Vitoria Maria
    de Paffer Filho, Silvio Hock
    AMERICAN HEART JOURNAL, 2021, 242 : 167 - 167
  • [32] SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Mahmoud Al Rifai
    L. Kristin Newby
    Ajith P. Nair
    Arunima Misra
    Joseph G. Rogers
    Savitri Fedson
    Salim S. Virani
    Current Atherosclerosis Reports, 2022, 24 : 627 - 634
  • [33] Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
    De Nicola, Luca
    Cozzolino, Mario
    Genovesi, Simonetta
    Gesualdo, Loreto
    Grandaliano, Giuseppe
    Pontremoli, Roberto
    JOURNAL OF NEPHROLOGY, 2022, 35 (06) : 1605 - 1618
  • [34] SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
    Razuk, V.
    Chiarito, M.
    Cao, D.
    Nicolas, J.
    Camaj, A.
    Power, D.
    Beerkens, F.
    Tavenier, A. H.
    Pivato, C.
    Mehran, R.
    Dangas, G.
    EUROPEAN HEART JOURNAL, 2021, 42 : 916 - 916
  • [35] Overcoming clinical inertia with SGLT-2 inhibitors: Strategies to accelerate adoption in heart failure
    Crowe, Byron
    Misra, Shantum
    Lee, Clement D.
    JOURNAL OF HOSPITAL MEDICINE, 2025, 20 (01) : 67 - 70
  • [36] Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care
    Velazquez, Eric J.
    Reinhardt, Samuel W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (18) : 2086 - 2088
  • [37] Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
    Luca De Nicola
    Mario Cozzolino
    Simonetta Genovesi
    Loreto Gesualdo
    Giuseppe Grandaliano
    Roberto Pontremoli
    Journal of Nephrology, 2022, 35 : 1605 - 1618
  • [38] SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai, Mahmoud
    Newby, L. Kristin
    Nair, Ajith P.
    Misra, Arunima
    Rogers, Joseph G.
    Fedson, Savitri
    Virani, Salim S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (08) : 627 - 634
  • [39] SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
    Silva-Cardoso, Jose
    Andrade, Aurora
    Brito, Dulce
    Ferreira, Jorge
    Fonseca, Candida
    Peres, Marisa
    Franco, Fatima
    Moura, Brenda
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2021, 40 (09) : 687 - 693
  • [40] SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?
    Verbrugge F.H.
    Vangoitsenhoven R.
    Mullens W.
    Van der Schueren B.
    Mathieu C.
    Tang W.H.W.
    Current Cardiovascular Risk Reports, 2015, 9 (8)